Heart Failure in the Diabetic Patient Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate Medical Group Heart Failure and Pulmonary Arterial Hypertension Programs Medical Director, Edward Hospital Center for Advanced Heart Failure Naperville, Illinois, U.S.A.
Heart Failure in the Diabetic Patient. Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate Medical Group Heart Failure and Pulmonary Arterial Hypertension Programs Medical Director, Edward Hospital Center for Advanced Heart Failure - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Heart Failure in the Diabetic Patient
Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A.Medical Director, Midwest Heart Specialists-Advocate Medical Group Heart Failure and Pulmonary Arterial Hypertension Programs
Medical Director, Edward Hospital Center for Advanced Heart FailureNaperville, Illinois, U.S.A.
“We demonstrate that young subjects with uncomplicated type 1 diabetes mellitus have impaired myocardial energetics irrespective of the duration of diabetes and that the impaired cardiac energetics status is independent of coronary microvascular function. We postulate that impairment of cardiac
energetics in these subjects primarily resultsfrom metabolic dysfunction rather than
microvascular impairment.”
Prevalence of DM in General Population with and without HF
Study/Date
No. of Subjects
Mean Age (yrs)
HF Prevalenc
e
Prevalence of DM with HF
Prevalence of DM without
HF
Rotterdam/01
5255 69 3.4% 17.5% 10.3%
Italy/97 1339 74 9.5% 29.6% 13.2%
Rekjavik/05
19381 - 3.8% 11.6% 3.4%
Olmstead /06
655 77 All with HF
13%-25% -
Prevalence of DM in Populations with and without LVSDStudy/Date
No. of Pts
Mean Age (yrs)
Definition of LVSD by EF
LVSD Pr1evalenc
e
Prevalence of
symptomatic LVSD
LVSD + DM
No LVSD, DM
ECHOES/01 3960 61 < 40 % 1.8% 1% 30% 3.8%
Copenhagen/03 764 66 ≤ 40% 4.7 67% 7.2% 5.9%
Poole/99 817 76 Visual Ass.
7.5% 21% 10% 6%
Glasgow/’97 1640 50 ≤ 35% 7.7% 23% 12.4% 2.5%
Vasteras/01 401 75 LWMI < 1.7%
6.8% 54% 22% 7%
Olmsted/03 1888 63 ≤ 50% 6.5% - 17% 6.8%
Copenhagen/05 188 69 < 45% 100% 100% 25.5% -
Prevalence of DM in Patients with HF in Clinical Trials